NCT02421939 2025-12-04A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationAstellas Pharma IncPhase 3 Completed371 enrolled 36 charts 2 FDA
NCT01564784 2019-01-09A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaPfizerPhase 3 Completed326 enrolled 33 charts 1 FDA